{"organizations": [], "uuid": "d2e4e580f69fba28ffad42def1c49132741ddcd4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abbvie-submits-marketing-authoriza/brief-abbvie-submits-marketing-authorization-application-to-ema-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis-idUSFWN1S8094", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T15:49:00.000+03:00", "replies_count": 0, "uuid": "d2e4e580f69fba28ffad42def1c49132741ddcd4"}, "author": "", "url": "https://www.reuters.com/article/brief-abbvie-submits-marketing-authoriza/brief-abbvie-submits-marketing-authorization-application-to-ema-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis-idUSFWN1S8094", "ord_in_thread": 0, "title": "BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-abbvie submits marketing authorization applica", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "moderate to severe plaque psoriasis reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 12:51 PM / Updated 11 minutes ago BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis Reuters Staff 1 Min Read\nMay 1 (Reuters) - AbbVie Inc:\n* ABBVIE SUBMITS MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR INVESTIGATIONAL TREATMENT RISANKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS\n* ABBVIE INC - APPLICATION SUPPORTED BY FOUR PIVOTAL PHASE 3 TRIALS EVALUATING MORE THAN 2,000 PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-01T15:49:00.000+03:00", "crawled": "2018-05-01T16:05:36.004+03:00", "highlightTitle": ""}